Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies

The treatment landscape for patients with advanced non-small cell lung cancer has evolved greatly with the advent of immune checkpoint inhibitors. However, many patients do not derive benefit from checkpoint blockade, developing either primary or secondary resistance, highlighting a need for alterna...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Robert J., Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339077/
https://www.ncbi.nlm.nih.gov/pubmed/32670423
http://dx.doi.org/10.1177/1758835920937902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339077/
https://www.ncbi.nlm.nih.gov/pubmed/32670423
http://dx.doi.org/10.1177/1758835920937902

Ejemplares similares